Abbott Libre 3 Receives CE Mark

Abbott announced it has received CE Mark for the Libre 3 CGM system. Unlike the Libre 1 and 2 CGM systems which require users to scan the sensor to receive their glucose readings, Libre 3 is a true real-time CGM. Additionally, Abbott has updated the Libre form factor with Libre 3 being approximately the size of two stacked US pennies. According to the press release, Abbott is planning for an EU launch “in the coming months” with no update on a potential US timeline. Below, FENIX provides thoughts on the new Libre 3 CGM features as well as potential implications to Dexcom, Medtronic, Senseonics, and other CGM manufacturers.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.